MS Views and News Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter

MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click:

Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Thursday, May 18, 2017

OhioHealth hospital was the first to use the FDA Approved Drug, Ocrevus

Click here to receive MS news via e-mail

Medical staff at OhioHealth's Neuroscience Center at Riverside Methodist Hospital became the first in the world to treat patients with a new FDA drug called Ocrevus in the battle against multiple sclerosis.
The significance of the drug lies in how it can slow what's called primary progressive multiple sclerosis. The manufacturer, Genentech, says it is the first and only disease-modifying therapy for primary progressive multiple sclerosis or PPMS.
Read more

MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis
MS Views and News provides beneficial information for those affected by Multiple Sclerosis.  
Join us by registering here: 

No comments: